Want to see UTHR full AI Analyst Report?
UTHR Stock Chart & Stats
$588.38
$3.82(1.05%)
At close: 4:00 PM EST
$588.38
$3.82(1.05%)
Day’s Range― - ―
52-Week Range$272.12 - $609.35
Previous CloseN/A
Volume58.00K
Average Volume (3M)503.60K
Market Cap
$23.22B
Enterprise Value$22.33B
Total Cash (Recent Filing)$2.15B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)18.7
Beta0.51
Next Earnings
Aug 05, 2026EPS Estimate
7.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)29.27
Shares Outstanding42,446,730
10 Day Avg. Volume365,211
30 Day Avg. Volume503,603
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue7.05
Enterprise Value/Gross Profit8.14
Enterprise Value/Ebitda13.03
Forecast
1Y Price Target
$663.13Price Target Upside12.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)27.99
Revenue Forecast (FY)$3.24B
Bulls Say, Bears Say
Bulls Say
Very High Profitability MarginsExceptionally high gross and operating margins reflect durable pricing power and a high-margin product mix centered on prostacyclin therapies. These margins provide long-term cash generation buffers to fund R&D and launches even if revenue growth lags, supporting sustainability over months.
Debt-free Balance Sheet And Strong Cash GenerationA zero-debt position and sizable equity give material financial flexibility for strategic investment and M&A. Strong absolute operating cash flow and positive free cash flow underpin the company’s ability to fund launches, commercial scale-up and organ-manufacturing initiatives without reliance on external financing.
Transformative Late-stage Clinical And Regulatory CatalystsRobust pivotal results for ralinepag and successful TETON data materially broaden addressable markets (PAH, IPF) and support near-term filings and launches. Positive phase III outcomes create durable commercial upside by expanding patient counts and enabling label extensions that can reshape long-term revenue trajectories.
Bears Say
Sharp Recent TTM Revenue DeclineA large trailing-twelve-month revenue drop signals material demand, pricing or volume disruption that can erode durability of earnings despite strong margins. If sustained, top-line weakness would pressure reinvestment plans and targets tied to new-product launches, making near-term growth assumptions less certain.
Volatile And Weakening Free Cash Flow GrowthAlthough absolute cash generation remains strong, recent FCF volatility reduces predictability for funding multiple simultaneous launches and manufacturing investments. Fluctuating FCF could constrain discretionary R&D, commercial scale spending, or organ‑manufacturing expansion if the trend persists over several quarters.
Regulatory, Bridging And Safety Execution RiskKey growth assumptions depend on smooth regulatory pathways, bridging studies and device approvals. Delays or additional study requirements can push launches, increase costs, and slow patient uptake. Safety limits for systemic agents in some lung populations further constrain addressable use and complicate commercial positioning.
United Therapeutics News
UTHR FAQ
What was United Therapeutics Corp.’s price range in the past 12 months?
United Therapeutics Corp. lowest stock price was $272.12 and its highest was $609.35 in the past 12 months.
What is United Therapeutics Corp.’s market cap?
United Therapeutics Corp.’s market cap is $23.22B.
When is United Therapeutics Corp.’s upcoming earnings report date?
United Therapeutics Corp.’s upcoming earnings report date is Aug 05, 2026 which is in 23 days.
How were United Therapeutics Corp.’s earnings last quarter?
United Therapeutics Corp. released its earnings results on May 06, 2026. The company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $6.998 by -$1.178.
Is United Therapeutics Corp. overvalued?
According to Wall Street analysts United Therapeutics Corp.’s price is currently Undervalued.
Does United Therapeutics Corp. pay dividends?
United Therapeutics Corp. does not currently pay dividends.
What is United Therapeutics Corp.’s EPS estimate?
United Therapeutics Corp.’s EPS estimate is 7.07.
How many shares outstanding does United Therapeutics Corp. have?
United Therapeutics Corp. has 42,446,730 shares outstanding.
What happened to United Therapeutics Corp.’s price movement after its last earnings report?
United Therapeutics Corp. reported an EPS of $5.82 in its last earnings report, missing expectations of $6.998. Following the earnings report the stock price went up 4.292%.
Which hedge fund is a major shareholder of United Therapeutics Corp.?
Currently, no hedge funds are holding shares in UTHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$663.13 (12.70% Upside)
$663.13 (12.70% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 127.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $190.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.25%
12-Months-Change
Fundamentals
Return on Equity
19.24%
Trailing 12-Months
Asset Growth
-13.30%
Trailing 12-Months
Company Description
United Therapeutics Corp.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTHR Stock 12 Month Forecast
Average Price Target
$663.13
▲(12.70% Upside)
Technical Analysis
Ownership Overview
1.96% Insiders
23.34% Mutual Funds
0.49% Other Institutional Investors
45.28% Public Companies and
Individual Investors